Definium Therapeutics, Inc. (DFTX)
| Market Cap | 4.90B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -237.54M |
| Shares Out | 109.07M |
| EPS (ttm) | -2.49 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 12,213,010 |
| Open | 44.70 |
| Previous Close | 44.79 |
| Day's Range | 42.84 - 45.75 |
| 52-Week Range | 6.40 - 47.01 |
| Beta | 2.38 |
| Analysts | Strong Buy |
| Price Target | 56.00 (+24.58%) |
| Earnings Date | Jul 30, 2026 |
About DFTX
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Defi... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 15 analysts, the average rating for DFTX stock is "Strong Buy." The 12-month stock price target is $56.0, which is an increase of 24.58% from the latest price.
News
A Breakthrough-Designated Depression Drug Is 86% Through Its Phase 3, With Topline Data Due This Year
Issued on behalf of Helus Pharma™ Helus Pharma™ (NASDAQ: HELP) (Cboe CA: HELP), the commercial operating name of Cybin Inc., says its APPROACH Phase 3 trial of HLP003 for adjunctive treatment of major...
Definium Therapeutics, Inc. Announces Closing of $805 Million Upsized Public Offering, Including Full Exercise of the Underwriters' Option to Purchase Additional Shares
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Biotech ETF Index Surges 10% After Rebalance
After a sweeping semi-annual rebalance, the biotech index underlying the ALPS Medical Breakthroughs ETF (SBIO) gained over 10% in just six trading days beginning June 18. Key Takeaways: SBIO's underly...
Definium Therapeutics rises 21.8%
Definium Therapeutics (DFTX) is up 21.8%, or $7.88 to $44.06.
Definium Therapeutics Stock (DFTX) Soars on a Public Offering Pricing After Strong Trial Results
Definium Therapeutics stock was up after the company priced a new $700 million public offering.
Definium Therapeutics rises 17.7%
Definium Therapeutics (DFTX) is up 17.7%, or $6.40 to $42.58.
Definium Therapeutics 20.6M share Secondary priced at $34.00
The deal size was increased to $700M in common stock from $500M in common stock. JPMorgan, Jefferies, Leerink and BofA acted as joint book running managers for the offering. Published…
Definium Therapeutics price target raised to $74 from $61 at JonesResearch
JonesResearch raised the firm’s price target on Definium Therapeutics (DFTX) to $74 from $61 and keeps a Buy rating on the shares after the company announced the Phase III Emerge…
Definium Therapeutics, Inc. Announces Pricing of $700 Million Upsized Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Definium Therapeutics price target raised to $57 from $37 at Baird
Baird analyst Christopher Chen raised the firm’s price target on Definium Therapeutics (DFTX) to $57 from $37 and keeps an Outperform rating on the shares. The firm updated its model…
Definium Therapeutics offers to sell $500M in common stock
Definium intends to use the net proceeds from this offering for the research and development of its product candidates, preparation activities for potential commercialization of DT120 ODT, if approved...
Definium Therapeutics, Inc. Announces Proposed Public Offering
NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) (the “Company” or “Definium”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intende...
Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’
As previously reported, Canaccord raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $38 and keeps a Buy rating on the shares, citing higher conviction in the…
Definium Therapeutics price target raised to $60 from $38 at Canaccord
Canaccord raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $38 and keeps a Buy rating on the shares.
Definium Therapeutics rises 55.9%
Definium Therapeutics (DFTX) is up 55.9%, or $13.68 to $38.16.
Definium Therapeutics price target raised to $60 from $40 at Oppenheimer
Oppenheimer raised the firm’s price target on Definium Therapeutics (DFTX) to $60 from $40 and keeps an Outperform rating on the shares.
Definium Therapeutics price target raised to $57 from $36 at RBC Capital
Following Definium Therapeutics (DFTX)’ call detailing the Phase 3 results from the Emerge study, RBC Capital raised the firm’s price target to $57 from $36 and keeps an Outperform rating…
Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win
Definium Therapeutics stock rallied alongside positive results from a Phase 3 clinical trial.
Definium can climb 50%-100% after ‘robust’ MDD data, says Jefferies
Jefferies analyst Andrew Tsai thinks Definium Therapeutics (DFTX)’ stock climbs higher by 50%-100% after “robust” 12-plus week Phase 3 data, noting that a single dose of DT120 safely produces rapid,…
Definium Therapeutics rises 55.7%
Definium Therapeutics (DFTX) is up 55.7%, or $13.64 to $38.12.
RBC Capital says would buy Definium Therapeutics after Phase III data
Definium Therapeutics (DFTX) reported that the Phase III EMERGE trial for DT120-ODT in major depressive disorder met all primary and secondary endpoints with a placebo-adjusted MADRS improvement of -8...
Definium Therapeutics DT120 data exceeds expectations, says Stifel
Stifel says “robust” major depressive disorder data reported by Definium Therapeutics (DFTX) for DT120 “exceeds expectations,” noting that the effect size of 8.1 points on MADRS at week-6 is “strong/d...
Definium Therapeutics Transcript: Study result
The phase III EMERGE study of DT120 ODT in MDD demonstrated rapid, robust, and durable efficacy, with an 8.1-point placebo-adjusted MADRS improvement at week six and strong safety. Benefits were consistent across subgroups, and the open-label extension showed sustained response. Regulatory discussions are ongoing, with pivotal GAD readouts expected soon.
Definium Therapeutics Press release: Study result
Definium Therapeutics issued a press release on June 22, 2026, disclosing material business information to investors.
Definium Therapeutics Slides: Study result
Definium Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on June 22, 2026.